However, low cancer cell TAP2 expression was associated with a significantly shorter OS and 82% increased risk of death only in patients treated with PD-1 axis blockers (Fig. 1F) (Cohort #4; HR 1.82 [CI: 1.12–2.96]). Here, TAP2 is linked to cancer.